Boundless Bio Inc (BOLD) Stock Price, Quote & News

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor s...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 766 9912

Website: boundlessbio.com

Address:

10955 Alexandria Way, Suite 100, San Diego, United States

MarketHunterr Jul. 5 at 10:38 PM

$BOLD weekly structure is being watched alongside recent insider activity and corporate actions tied to the Serapha Bio merger. A key point in the setup is the proposed special dividend, with Boundless indicating potential excess net cash distribution of ~$44–$48M to shareholders. While insider buying and capital return plans can support sentiment, price action will still depend on post-merger execution and liquidity conditions.

0 · Reply

CosmicMiner Jul. 5 at 9:17 PM

Notable Insider Buys This Week: $BBD: $2.0M across 2 buys, Jul 1 $NVCT: $1.17M combined across 2 buys (2 insiders), Jun 30 $BOLD: $984K across 10 separate buys by one Chairman $CREX: $800K combined across 2 buys (CEO + CFO same day), Jun 30 $MDV: $163K across 4 buys by CEO (steady accumulation) "A lot of great opportunities if you know where to look. The battle map has been shared in the community! Are you going to miss out again?"

0 · Reply

AlertsAndNews Jul. 3 at 8:03 PM

$BOLD TANG Capital Management LLC (10%+) purchased 107,463 shares at an average price of $2.50 (Form 4). Another form 4 here.

0 · Reply

JuggernautRaider Jul. 1 at 8:09 AM

$BOLD $ATRA i cannot wait to short these turds. Flush the toilet!🚽

0 · Reply

JuggernautRaider Jun. 30 at 1:11 PM

$BOLD @race2zerodo you want to short this dying company?

0 · Reply

AlertsAndNews Jun. 30 at 2:54 AM

$BOLD quite the 10%+er buy TANG Capital Management LLC (10%+) purchased 286,333 shares at an average price of $2.50 (Form 4).

0 · Reply

ikkydiphoenix Jun. 30 at 12:21 AM

$BOLD https://ca.investing.com/news/stock-market-news/tang-capital-management-acquires-714768-of-boundless-bio-stock-93CH-4712818

0 · Reply

JuggernautRaider Jun. 29 at 8:26 PM

$BOLD might short this shit, why not. Theur CEO is below average at best

0 · Reply

stockanalysis_ Jun. 27 at 2:19 PM

Weekly Gainers: $ILLR $SDOT $FCUV $ATLN $BOLD

0 · Reply

bananastand1203 Jun. 25 at 2:35 PM

$PRME anyone selling given $BOLD news and upcoming arbitration outcome? Feeling that there are more headwind than positive developments in short term, with the greatest headwind being another dilutive raise

3 · Reply

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

NDRA

2026-06-23T13:43:46.000Z - 12 days ago

Boundless Bio, Serapha Bio to combine in all-stock merger

Jun 23, 2026, 8:30 AM EDT - 12 days ago

Boundless Bio Transcript: M&A announcement

Jun 23, 2026, 8:30 AM EDT - 12 days ago

Boundless Bio Press release: M&A announcement

Jun 23, 2026, 7:30 AM EDT - 12 days ago

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

2026-05-08T11:19:39.000Z - 2 months ago

Boundless Bio reports Q1 EPS (60c), consensus (56c)

May 8, 2026, 7:00 AM EDT - 2 months ago

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

May 8, 2026, 7:00 AM EDT - 2 months ago

Boundless Bio Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 2 months ago

Boundless Bio Earnings release: Q1 2026

May 8, 2026, 7:00 AM EDT - 2 months ago

Boundless Bio Slides: Corporate presentation

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Boundless Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Boundless Bio Proxy statement: Proxy filing

2026-04-17T21:00:47.000Z - 2 months ago

Boundless Bio presents preclinical data for BBI-940 therapy at AACR

Apr 17, 2026, 4:49 PM EDT - 2 months ago

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Mar 17, 2026, 4:52 PM EDT - 3 months ago

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Mar 11, 2026, 11:20 AM EDT - 4 months ago

Boundless Bio Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:06:21.000Z - 4 months ago

Boundless Bio sees cash runway into 2H28

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Boundless Bio Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Boundless Bio Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Boundless Bio Slides: Corporate presentation

Mar 4, 2026, 7:00 AM EST - 4 months ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 12, 2026, 3:00 PM EST - 5 months ago

Boundless Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 5 months ago

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-20T12:16:02.000Z - 5 months ago

Boundless Bio announces FDA accepted IND application of BBI-940

2026-01-20T12:15:45.000Z - 5 months ago

Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825

Jan 20, 2026, 7:00 AM EST - 5 months ago

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Dec 3, 2025, 9:30 AM EST - 7 months ago

Boundless Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 7 months ago

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-11-05T12:06:32.000Z - 8 months ago

Boundless Bio reports Q3 EPS (62c), consensus (58c)

2025-11-05T12:05:53.000Z - 8 months ago

Boundless Bio sees cash runway into 1H28

Nov 5, 2025, 7:00 AM EST - 8 months ago

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 5, 2025, 7:00 AM EST - 8 months ago

Boundless Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Boundless Bio Earnings release: Q3 2025

Oct 13, 2025, 4:05 PM EDT - 9 months ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-08-11T10:15:45.000Z - 11 months ago

Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright

2025-08-05T11:13:07.000Z - 11 months ago

Boundless Bio reports Q2 EPS (70c), consensus (65c)

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Boundless Bio Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Boundless Bio Quarterly report: Q2 2025

2025-07-24T20:55:16.000Z - 1 year ago

Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs

Jun 9, 2025, 9:20 AM EDT - 1 year ago

Boundless Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 4:58 PM EDT - 1 year ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

2025-06-02T10:15:17.000Z - 1 year ago

Boundless Bio initiated with a Buy at H.C. Wainwright

2025-05-27T20:40:07.000Z - 1 year ago

Boundless Bio downgraded to Market Perform from Outperform at Leerink

May 27, 2025, 8:00 AM EDT - 1 year ago

Boundless Bio Transcript: Status Update

2025-05-23T20:05:14.000Z - 1 year ago

Boundless Bio discontinuing BBI-355 and BBI-825 programs

May 23, 2025, 4:01 PM EDT - 1 year ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 9, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 6:00 PM EDT - 1 year ago

Boundless Bio Earnings release: Q1 2025

May 8, 2025, 6:00 PM EDT - 1 year ago

Boundless Bio Quarterly report: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Boundless Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Boundless Bio Proxy statement: Proxy Filing

Apr 3, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

2025-04-01T20:05:11.000Z - 1 year ago

Boundless Bio files $400M mixed securities shelf

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Boundless Bio Registration statement: Registration Filing

2025-03-27T11:07:19.000Z - 1 year ago

Boundless Bio reports Q4 EPS (74c) vs ($9.76) last year

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Annual report: Q4 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Earnings release: Q4 2024

Mar 12, 2025, 11:20 AM EDT - 1 year ago

Boundless Bio Transcript: Leerink Global Healthcare Conference 2025

Feb 26, 2025, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

2025-02-03T15:05:25.000Z - 1 year ago

Boundless Bio appoints Robert Doebele as CMO

Feb 3, 2025, 10:00 AM EST - 1 year ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

2024-12-13T14:05:18.000Z - 1 year ago

Boundless Bio downgraded to Neutral at Guggenheim after BBI-825 scrapped

Dec 12, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Announces Pipeline and Leadership Updates

Dec 4, 2024, 3:30 PM EST - 1 year ago

Boundless Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 12, 2024, 2:30 PM EST - 1 year ago

Boundless Bio Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:00 PM EST - 1 year ago

Boundless Bio Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Boundless Bio Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Sep 18, 2024, 10:20 AM EDT - 1 year ago

Boundless Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 4:00 PM EDT - 2 years ago

Boundless Bio Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

Boundless Bio Earnings release: Q2 2024

Jun 12, 2024, 3:20 PM EDT - 2 years ago

Boundless Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Boundless Bio Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Earnings release: Q1 2024

May 12, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Slides: Corporate Presentation

May 6, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Mar 27, 2024, 6:55 PM EDT - 2 years ago

Boundless Bio Announces Pricing of Initial Public Offering

MarketHunterr Jul. 5 at 10:38 PM

0 · Reply

CosmicMiner Jul. 5 at 9:17 PM

0 · Reply

AlertsAndNews Jul. 3 at 8:03 PM

$BOLD TANG Capital Management LLC (10%+) purchased 107,463 shares at an average price of $2.50 (Form 4). Another form 4 here.

0 · Reply

JuggernautRaider Jul. 1 at 8:09 AM

$BOLD $ATRA i cannot wait to short these turds. Flush the toilet!🚽

0 · Reply

JuggernautRaider Jun. 30 at 1:11 PM

$BOLD @race2zerodo you want to short this dying company?

0 · Reply

AlertsAndNews Jun. 30 at 2:54 AM

$BOLD quite the 10%+er buy TANG Capital Management LLC (10%+) purchased 286,333 shares at an average price of $2.50 (Form 4).

0 · Reply

ikkydiphoenix Jun. 30 at 12:21 AM

$BOLD https://ca.investing.com/news/stock-market-news/tang-capital-management-acquires-714768-of-boundless-bio-stock-93CH-4712818

0 · Reply

JuggernautRaider Jun. 29 at 8:26 PM

$BOLD might short this shit, why not. Theur CEO is below average at best

0 · Reply

stockanalysis_ Jun. 27 at 2:19 PM

Weekly Gainers: $ILLR $SDOT $FCUV $ATLN $BOLD

0 · Reply

bananastand1203 Jun. 25 at 2:35 PM

3 · Reply

DayTrade_4Life Jun. 25 at 7:55 AM

👀Some stocks to watch for 25 June: AMS AZI WAVE FMFC SKYQ $ICCM $BOLD $UBXG 👉See Profile to Join Us.

0 · Reply

Bootsy_Collins Jun. 24 at 2:40 PM

$BOLD Shorting back to a dollar

1 · Reply

JuggernautRaider Jun. 24 at 2:12 PM

$BOLD looking juicy for action either way 🤫

0 · Reply

Jdiology Jun. 24 at 1:38 PM

$BOLD 🎯🎯

0 · Reply

stockwitsuser2449 Jun. 24 at 12:23 PM

$BOLD leaving this til the dust settles then will reenter for a short postion.

0 · Reply

ShKumaresan Jun. 24 at 2:54 AM

$BOLD $BLZE $QNT Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today https://stocktwits.com/news-articles/markets/equity/why-did-bold-blze-qnt-stocks-surge-to-52-week-highs-today/cZKUHYtR7OQ

0 · Reply

StocktwitsNews Jun. 24 at 2:53 AM

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today $BLZE $BOLD $QNT $CRWV https://stocktwits.com/news/equity/markets/why-did-bold-blze-qnt-stocks-surge-to-52-week-highs-today/cZKUHYtR7OQ

0 · Reply

TeamBullish Jun. 24 at 2:50 AM

The Stock Market made me a millionaire, maybe that’s why I show up everyday, and truly believe in it. Anyone can make the American dream come true. $ATLN $SPCX $FCUV $SPY $BOLD

2 · Reply

Stock_Catcher Jun. 24 at 1:46 AM

Wealthy Wednesday Watchlist Continuation $CIIT $CRMT $FOFO $BOLD $YMAT

0 · Reply

SilentNome Jun. 24 at 1:44 AM

$BOLD they will drag this to $1

0 · Reply

topstockalerts Jun. 24 at 1:43 AM

Top Gainers $ATLN $ADTX $FCUV $BOLD $CIIT

0 · Reply

SadyK189 Jun. 24 at 12:56 AM

Top Stocks to watch tomorrow 2 / 2: $FCUV $OTLK $BOLD $LFS $NIXX OTLK: Initially alerted at 0.54. Kept posting about it regularly. Currently at 1.70 with key support zone at 1.10 - 1.23 now. Next key level to test 2.05 - 2.25. FCUV: Looking good on 4hours chart. 3.2 - 3.5 is acting as key support zone. Next key level to test 5.4 - 5.8. Currently at 4.68 LFS: Looking good on 4hours chart and held key support zone of 1.95 - 2.15 nicely so far. Next key level to test 3.5 - 3.85. Currently at 2.98 BOLD: Good close of daily candle. Key support zone at 2 - 2.20. Next key level to test 3.15 - 3.40. Currently at 2.68 NIXX is moving slowly and steadily but nicely on daily chart. Updated support zone at 1 - 1.09. Next key level to test 1.9 - 2.15. Currently at 1.47

2 · Reply

Market Cap	56.16M
Revenue (ttm)	0.00
Net Income (ttm)	-58.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	143,900
Avg Vol	1,502,834
Day's Range	N/A - N/A
Shares Out	22.46M
Stochastic %K	79%
Beta	-0.07
Analysts	Hold
Price Target	$4.00